中华放射肿瘤学杂志
Sunday, Apr. 6, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2021, Vol. 30 Issue (4): 353-356    DOI: 10.3760/cma.j.cn113030-20210127-00046
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer
Zeng Cheng1,2, Yang Dan1, Du Rongxu1, Jiang Leilei1, Dong Xin1, Li Dongming1, Yu Rong1, Yu Huiming1, Shi Anhui1
1Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Peking University College of Clinical Oncology, Beijing 100142, China;
2Department of Oncology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan 430070, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective The standard treatment for inoperable locally advanced esophageal cancer is concurrent chemoradiotherapy, but the survival was not satisfied. Nituzumab is a humanized IgG monoclonal antibody against EGFR. The purpose of this study is to investigate the toxicity and efficacy of concurrent chemoradiotherapy combined with nituzumab for locally advanced esophageal cancer. Methods We retrospectively reviewed the clinical data of locally advanced esophageal cancer who were treated with concurrent chemoradiotherapy combined with nituzumab in Peking University Cancer Hospital from June 2015 to June 2020. Kaplan-Meier method was used for analysis. Results Thirty Patients were enrolled this study.After a median follow-up of 22.5 months, The objective response rate was 93%. The 1-year, 2-year, 3-year overall survival rates were 83%, 57% and 41%,with the progression-free survival rates 75%, 47% and 32%, with the local-recurrence free survival rates 83%, 53% and 37%, with the metastasis-free survival rates 75%, 51% and 36%, respectively.The incidence of grade≥3 hematological toxicity was 32%. There were 16% patients experiencing grade≥3 esophagitis. Conclusion The preliminary result of concurrent chemoradiotherapy combined with nituzumab is effective and safe for patients with locally advanced esophageal cancer.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Zeng Cheng
Yang Dan
Du Rongxu
Jiang Leilei
Dong Xin
Li Dongming
Yu Rong
Yu Huiming
Shi Anhui
Key wordsEsophageal neoplasms/concurrent chemoradiotherapy      Esophageal neoplasms/target therapy      Treatment outcome     
Received: 27 January 2021     
Fund:Beijing Municipal Health Commission (BHTPP202026)
Corresponding Authors: Shi Anhui, Email:anhuidoctor@163.com   
Cite this article:   
Zeng Cheng,Yang Dan,Du Rongxu et al. Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 353-356.
Zeng Cheng,Yang Dan,Du Rongxu et al. Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 353-356.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210127-00046     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I4/353
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn